NHS England Innovative Drug Scorecard Paints Unbalanced, Unclear Access Picture
This article was originally published in Scrip
Latest collected data of patient access in England to recently launched drugs again shows low uptake of such therapies and underscores the need for revamping the way modern medicines are made available to patients in the UK, according to the Association of the British Pharmaceutical Industry.
You may also be interested in...
The Novo Nordisk Foundation is sponsoring a panel at Davos this week on finding solutions to the global crisis on antimicrobial resistance – and hopes world leaders will listen.
A Phase III clinical trial comparing AbbVie's Skyrizi with Novartis's IL-17 agonist Cosentyx showed the former's superiority in adults with moderate-to-severe plaque psoriasis.
Acasti’s omega-3 candidate drug CaPre missed the primary endpoint in TRILOGY-1 due to an unexplained high placebo effect, as AstraZeneca said its STRENGTH study was unlikely to show a treatment benefit.